Elsevier launches drug analysis laboratory tool
set to greatly benefit laboratory researchers working in the
pharmaceutical and biotech professionals by bringing together drug
characteristics and status within a database.
The launch of the Inteleos tool is part of Elseiver's suite of business intelligence methods for the pharmaceutical and biotech markets, which are to be launched over the course of 2006 and 2007 and will include a consultancy service and syndicated reports.
Inteleo's designers >Elsevier, has developed a database of over 8,000 drugs, which also includes medical conference news from Elsevier's IMNG, weekly updates from The Pink Sheets, and ontology files of 1.25 million terms to enhance searching.
With Inteleos, users can track and analyse drug activity from late-phase preclinical development through to launch and post-marketing studies. Users can also monitor licensing, or merger and acquisition activities with ease.
Inteleos offers a unique combination of features and functionality to help users save valuable time and increase efficiency.
"Our team has shown real commitment to customer focus in bringing Inteleos to market," says Brian Nairn, CEO of Elsevier Health Sciences.
The customer experience is at the core of everything that we do. From the beginning, we've worked to develop tools that enable intelligence professionals to make actionable business decisions.
Elseiver has entered the business intelligence market with a view to targeting business intelligence needs - for competitive analysis or to determine licensing opportunities - of the pharmaceutical and biotech professional sector.
Nairn said that feedback from users in the specialist fields were responsible for the research and development of the database.
"The Inteleos editorial team adheres to strict editorial guidelines," he said. "The database is updated daily using only primary sources direct from drug companies, regulatory agencies, or financial filings."
In addition to breadth and depth of coverage, the Inteleos interface is clean and easy to use.
"Users can personalise the search experience with tools that facilitate easy organisation and monitoring of drugs, companies and therapy areas," explains Julie Gordon, director of Emerging Products.
"They have the flexibility to run simple or complex searches using a wide set of parameters and the ability to quickly and easily develop graphical representations of scenarios with state-of-the-art analysis tools," she added.
The Inteleos database will be available commercially in May 2006.
